Cerus has restated its two MidCap credit agreements, borrowing a first $35.0 million on a term loan that can reach $65.0 million. Its revolver had $29.9 million outstanding at closing, and the term loan is priced at Term SOFR plus 5.50%.
Latest CERUS CORP news
We have not published a story on CERUS CORP yet. When there is news, it will appear here.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $18.0 million, plus short-term investments of $38.3 million, $56.3 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about CERUS CORP
What is the ticker symbol of CERUS CORP?
CERUS CORP trades under the ticker CERS on NASDAQ.
Where is CERUS CORP listed?
CERUS CORP is listed on NASDAQ.
Which country or territory is CERUS CORP listed under?
Our directory records CERUS CORP under United States.
Does aibio.space cover CERUS CORP?
aibio.space lists CERUS CORP among 2,820 public biotech companies and publishes its news here as stories appear.
Is CERUS CORP profitable?
CERUS CORP reported a net loss of $15.6 million for the fiscal year ended Dec 31, 2025, and generated $4.8 million of cash from operations, per its annual report to the SEC.
How much does CERUS CORP spend on research and development?
$67.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does CERUS CORP have?
$56.3 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest CERUS CORP (CERS) stock news?
Our latest story on CERUS CORP, dated Jun 5, 2026: "Cerus takes up to $65.0 million secured term loan from MidCap". Cerus has restated its two MidCap credit agreements, borrowing a first $35.0 million on a term loan that can reach $65.0 million. Its revolver had $29.9 million outstanding at closing, and the term loan is priced at Term SOFR plus 5.50%. Source.
Does CERUS CORP have debt, a term loan or convertible notes?
Our latest debt story, dated Jun 5, 2026: "Cerus takes up to $65.0 million secured term loan from MidCap". Cerus has restated its two MidCap credit agreements, borrowing a first $35.0 million on a term loan that can reach $65.0 million. Its revolver had $29.9 million outstanding at closing, and the term loan is priced at Term SOFR plus 5.50%. Source.
How can I follow CERUS CORP (CERS) news?
Press Follow on this page to add CERUS CORP to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming CERUS CORP so far, in Debt Financing.
Investor discussion: CERUS CORP
Members talk about CERUS CORP (CERS). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:CERS on TradingView.
Listing details
CERUS CORP is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CERS, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Company
CERUS CORP
Ticker
CERS
Listing
NASDAQ
Country or territory
United States
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction